Gyre Therapeutics, Inc. GYRE Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s deferred tax assets?
- Gyre Therapeutics, Inc. (GYRE) reported deferred tax assets of $7.72M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s deferred tax assets changed year-over-year?
- Gyre Therapeutics, Inc.'s deferred tax assets increased by 32.7% year-over-year, from $5.82M to $7.72M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s deferred tax assets?
- Over 3 years (2022 to 2025), Gyre Therapeutics, Inc.'s deferred tax assets has grown at a 19.0% compound annual growth rate (CAGR), from $4.08M to $6.87M.
- What does deferred tax assets mean?
- Represents future tax benefits arising from temporary differences between the book value of assets/liabilities and their tax basis, or from carry-forward tax losses. These assets are realized when the firm generates sufficient taxable income to offset these differences. It serves as an indicator of future tax savings potential.